|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A re- view of the evidence for active preoperative warming of adults undergoing general anesthesia 显示文摘 | Roberson MC Dieckmann LS Rodriguez RE | 2013 | Aana J2013，81，5： | 1 |
| 2 | All-trans-retinoic acid-induced myositis:a description of two patieats 显示文摘 | Van Der Vliet Roberson HJ Hogan MC | | Am-J-Hematol0，63，： | 1 |
| 3 | LY2439821,a humanized anti-interleukin-17 monoclonal antibody,in the treat-ment of patients with rheumatoid arthritis:A phase I randomized,double-blind,placebo-controlled,proof-of-concept study显示文摘 | Genovese MC Van den Bosch F Roberson SA | 2010 | Ar-thritis Rheum2010，62，4： | 1 |
| 4 | LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo- controlled, proof-of-concept study显示文摘 | Genovese MC van den Bosch F Roberson SA | 2010 | Arthritis Rheum2010，62，4： | 1 |
| 5 | LY2439821, a humanized anti- interleukin- 17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double- blind, placebo-controlled, proof- of- concept study 显示文摘 | Genovese MC Van den Bosch F Roberson SA et aI | 2010 | Arthritis Rheum2010，62，4： | 1 |
| 6 | A hum- anized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, do- ubleblind, placebo-controlled, proof-of-concept study显示文摘 | Genovese MC Van den Bosch F Roberson SA | 2010 | Arthritis Rheum2010，62，4： | 1 |
| 7 | LY2439821,a humanized anti-interleukin-17 monoclonal antibody,in the treatment of patients with rheumatoid arthritis:a phase Ⅰ randomized,double-blind,placebo-controlled,proof-of-concept study显示文摘 | Genovese MC Van den Bosch F Roberson SA | 2010 | Arthritis Rheum2010，64，4： | 1 |
| 8 | LY2439821,a humanized anti-interleukin-17 monoclonal antibody,in the treatment of patients with rheumatoid arthritis:a phase I randomized,double-blind,placebo-controlled,proof-of-concept study显示文摘 | Genovese MC Van den Bosch F Roberson SA | 2010 | Arthritis Rheum2010，62，： | 1 |
| 9 | LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo- controlled, proof-of -concept study 显示文摘 | Genovese MC Van den Bosch F Roberson SA | 2010 | Arthritis Rheum2010，62，4： | 1 |
| 10 | A review of the evidence for active preoperative warming of adults undergo- ing general anesthesia显示文摘 | Roberson MC Dieckmann LS Rodriguez RE | 2013 | AANA J2013，81，5： | 1 |
| 11 | LY243-9821,a humanized anti-interleukin-17 monoclonal anti-body,in the treatment of patients with rheumatoid arthritis:a phase Ⅰ randomized,double-blind,placebo-controlled,proof-of-concept study显示文摘 | Genovese MC Van den Bosch F Roberson SA | | 0，，： | 1 |
| 12 | LY2439821, a humanized Anti-Interleukin 17 monoclonal antibody, in the treatment of patients with rheumatoid ar- thritis a phase I randomized, Double-Blind, Placebo- Controlled, Proof-of-Concept study显示文摘 | Genovese MC Van Den Bosch F Roberson SA | 2010 | Arthritis Rheum2010，62，4： | 1 |
| 13 | LY2439821,a humanized anti-IL-17 monoclonal antibody,in the treatment of patients with rheumatoid arthritis:a phase Ⅰ randomized,doubleblind,placebo-controlled,proof-of-concept study显示文摘 | Genovese MC Van den Bosch F Roberson SA | 2010 | Arthritis Rheum2010，62，4： | 1 |
| 14 | LY2439821, a Humanized Anti -Interleukin -17 Monoclonal Antibody, in the Treatment of Patients With Rheumatoid Arthritis A Phase I Randomized,Double-Blind,Placebo- Controlled, Proof -of -Concept Study 显示文摘 | Genovese MC Van den Bosch F Roberson SA | 2010 | Arthritis and Rheumatism2010，62，4： | 1 |
| 15 | LY2439821, a humanized anti-interleukin- 17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis:A phase I randomized, double-blind,placebo-controlled,proof-o f-concept study显示文摘 | Genovese MC Bosch FV Roberson SA et aI | 2010 | Arthritis Rheum2010，62，4： | 1 |
| 16 | LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis : A phase I randomized, double-blind, placebo-controlled, proof-of- concept study显示文摘 | Genovese MC Van den Bosch F Roberson SA | 2010 | Arthritis Rheum2010，62，4： | 1 |
| 17 | Factors associated with increased incidence of severe toxicities following yttrium-90 resin microspheres in the treatment of hepatic malignancies显示文摘AIM: To further define variables associated with increased incidences of severe toxicities following administration of yttrium-90(^(90)Y) microspheres. METHODS: Fifty-eight patients undergoing 79 treatments were retrospectively assessed for development of clinical and laboratory toxicity incidence following ^(90)Y administration. Severe toxicity events were defined using Common Terminology Criteria for Adverse Events version 4.03 and defined as grade ≥ 3. Univariate logistic regression analyses were used to evaluate the effect of different factors on the incidence of severe toxicity events. Multicollinearity was assessed for all factors with P < 0.1 using Pearson correlation matrices. All factors not excluded due to multicollinearity were included in a multivariate logistic regression model for each measurement of severe toxicity.RESULTS: Severe(grade ≥ 3) toxicities occurred following 21.5% of the 79 treatments included in our analysis. The most common severe laboratory toxicities were severe alkaline phosphatase(17.7%), albumin(12.7%), and total bilirubin(10.1%) toxicities. Decreased pre-treatment albumin(OR = 26.2, P = 0.010) and increased pre-treatment international normalized ratio(INR)(OR = 17.7, P = 0.048) were associated with development of severe hepatic toxicity. Increased pre-treatment aspartate aminotransferase(AST; OR = 7.4, P = 0.025) and decreased pre-treatment hemoglobin(OR = 12.5, P = 0.025) were associated with severe albumin toxicity. Increasing pre-treatment model for end-stage liver disease(MELD) score(OR = 1.8, P = 0.033) was associated with severe total bilirubin toxicity. Colorectal adenocarcinoma histology was associated with severe alkaline phosphatase toxicity(OR = 5.4, P = 0.043).CONCLUSION: Clinicians should carefully consider pre-treatment albumin, INR, AST, hemoglobin, MELD, and colorectal histology when choosing appropriate candidates for ^(90) Y microsphere therapy. | John D Roberson II Andrew M Mc Donald Craig J Baden Chee Paul Lin Rojymon Jacob Omer L Burnett III | 2016 | World Journal of Gastroenterology2016，22，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员